|Year : 2018 | Volume
| Issue : 3 | Page : 349-354
Should we prescribe ursodeoxycholic acid after laparoscopic sleeve gastrectomy? A two-center prospective randomized controlled trial
Tarek A.O Abouzeid1, Ahmed A.A Shoka2
1 Department of General Surgery, College of Medicine, Ain-Shams University, Cairo; General and Laparoscopic Surgery, Abha Private Hospital, Abha
2 Department of General Surgery, College of Medicine, Ain-Shams University, Cairo, Egypt
|Date of Submission||19-Feb-2018|
|Date of Acceptance||19-Mar-2018|
|Date of Web Publication||17-Aug-2018|
Tarek A.O Abouzeid
Department of General and Laparoscopic Surgery, College of Medicine, Ain-Shams University, Cairo, 11566, Egypt
Source of Support: None, Conflict of Interest: None
Background In the recent era, laparoscopic sleeve gastrectomy (LSG) had emerged as a safe and effective bariatric procedure. Rapid weight loss is associated with deranged cholesterol metabolism in the form of gallstones. Several studies have shown that ursodeoxycholic acid (UDCA) has a prophylactic role after gastric bypass, vertical banded gastroplasty, and adjustable gastric banding. Yet, data about its effect after LSG are scarce. In this study, we tried to unveil the prophylactic role of UDCA in the prevention of post-LSG gallstones.
Materials and methods This two-center prospective randomized controlled trial had been conducted at Abha Private Hospital, Saudi Arabia, and Ain-Shams University hospitals, Egypt, from May 2016 to June 2017 on 89 post-LSG patients. After block randomization, patients were allocated into either group A (UDCA treatment) or group B (control). UDCA was prescribed as 250 mg twice daily for 12 months or until the development of gallstones.
Results A total of 44 patients were included in group A and 45 patients were included in group B. There was no significant difference between both the groups regarding the baseline parameters. At the sixth month, group A showed a significantly lower incidence of gallstones (6.8 vs. 22.2% in group B; P=0.028). This pattern was maintained till the 12th month (5.8 vs. 14.7%; P=0.031). The overall percentage of gallstones was 23.5% (20/85); it was significantly higher in the first 6 months than in the second 6 months (14.6 vs. 9.7%; P=0.043).
Conclusion UDCA is a safe prophylactic measure against gallstones formation and should be integrated into the post-LSG prescription.
Keywords: cholelithiasis, gallstone prevention, laparoscopic sleeve gastrectomy, postlaparoscopic sleeve complications, ursodeoxycholic acid
|How to cite this article:|
Abouzeid TA, Shoka AA. Should we prescribe ursodeoxycholic acid after laparoscopic sleeve gastrectomy? A two-center prospective randomized controlled trial. Egypt J Surg 2018;37:349-54
|How to cite this URL:|
Abouzeid TA, Shoka AA. Should we prescribe ursodeoxycholic acid after laparoscopic sleeve gastrectomy? A two-center prospective randomized controlled trial. Egypt J Surg [serial online] 2018 [cited 2019 Sep 20];37:349-54. Available from: http://www.ejs.eg.net/text.asp?2018/37/3/349/239117
| Introduction|| |
In the recent era, laparoscopic sleeve gastrectomy (LSG) had emerged as a safe and effective bariatric procedure in terms of adequate weight loss and low complication rate ,,. Nevertheless, the rapid significant weight loss can disturb biliary cholesterol homeostasis and may lead to gallstone formation ,,,. Cholelithiasis is one of the commonest complications after LSG; it accounts for 15–47.9% ,,.
Laparoscopic cholecystectomy after LSG may be technically challenging, and serious complications have been reported in 2–3% of cases ,,. Hence, the prevention of stones is of utmost importance.
The prevention of post-LSG gallstone is a highly controversial issue; to date, no consensus exists about its prevention. Several preventive approaches had been proposed like preventive, concomitant, and postoperative cholecystectomy ,, and prostaglandin inhibitors (such as Ibuprofen) , but they were either controversial or unsuccessful .
Ursodeoxycholic acid (UDCA) is a naturally occurring hydrophilic secondary bile acid  extracted from the Chinese dark bear ,. It was approved by the US Food and Drug Administration and is used successfully in the treatment of several hepatobiliary diseases . It increases biliary acids, favors the formation of biliary micelles and vesicles ,,, reduces intestinal absorption and biliary secretion of cholesterol and mucin, and decreases cholesterol saturation index to be less than one, hence decreasing the bile lithogenicity ,,.
Several studies have settled that UDCA has a prophylactic role against gallstone formation after Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrectomy (VBG), and adjustable gastric banding (AGB) ,,,. Yet, there is a paucity of data regarding its effect after LSG. In this study, we tried to unveil the prophylactic role of UDCA in the prevention of post-LSG gallstones.
| Materials and methods|| |
This two-center, parallel-group, superiority, prospective randomized controlled trial had been conducted from May 2016 to June 2017 upon separate approval of the Institutional Review Board of each center. The first center was Ain-Shams University hospitals, Cairo, Egypt, and the second center was Abha Private Hospital, located in Abha, Saudi Arabia.
Post-LSG patients aged 18–65 years, of both sexes irrespective of ethnicity, were recruited to participate in the study. All our patients had a routine preoperative transabdominal ultrasound (US) surveillance to exclude the presence of gallstones or sludge. Exclusion criteria included preoperative cholelithiasis and/or sludge, gallbladder polyp(s), known allergy to UDCA, previous cholecystectomy, dilated common bile duct, deranged liver function tests, bleeding disorders, and those unfit for general anesthesia.
Eligible patients have been enrolled in the trial after submitting an informed written consent. They were randomized using the permuted block randomization method with an allocation ratio of 1 : 1. Such method ensures balancing of the number of the patients to both arms of the trial every ten recruits, and then they were allocated to either UDCA treatment (group A) or control group (group B). For group A patients, UDCA (Ursofalk; Dr. Falk Pharma, Freiburg, Germany) was prescribed as one tablet 250 mg twice daily starting within 3 days postoperatively and continuing for 12 months or until gallstone development. At discharge, all patients had full verbal and written instructions regarding the post-LSG complications and the symptoms of gallstones and were instructed to report it and to follow-up immediately.
The follow-up visits were scheduled for 3, 6, 9, and 12 months postoperatively. In each follow-up visit, the patients were clinically assessed, some weight loss parameters were calculated as BMI and percentage excess weight loss (%EWL), with the assessment of the compliance to treatment and detection of any UDCA-related adverse effects. US study was requested routinely at the sixth and 12th month follow-up visit only. Primary outcome measures included the formation of gallstones or UCDA-related adverse effects, whereas secondary outcome measures were the development of complications related to the gallstones and/or laparoscopic cholecystectomy.
Demographic data such as age, sex, and anthropometric data such as height, weight, BMI, and %EWL, and percentage of gallstones in each group were documented. Dropout patients and those who developed adverse effects related to UDCA administration were excluded from the study at the time of detection. We stopped US scanning once obtaining the positive US of gallstones, and their results were excluded from the next analysis at the 12th month (Flowchart 1)
. All relevant data were documented in a special Excel sheet for Windows (Microsoft Corporation, Redmond, Washington, USA) and were verified to check its statistical significance.
The standard descriptive statistics were used to summarize the demographic, anthropometric, and clinical data. The quantitative continuous variables with a normal distribution were expressed as the mean±SD, and qualitative data with categorical variables were expressed as frequencies and proportions.
The categorical variables were analyzed by the Fisher’s exact test or χ2-test. Univariate analyses for the continuous variables were performed by the Wilcoxon–Mann–Whitney test (also called Wilcoxon’s rank-sum test), which is an accurate nonparametric test applied for data with non-normal distributions of two independent groups. The statistical analysis was performed using the statistical package for the social sciences version 22 software package (SPSS Inc., Chicago, Illinois, USA). P value of less than 0.05 is considered statistically significant.
| Results|| |
During the period of study, 123 patients underwent LSG in the two institutions. Overall, 24 patients were excluded owing to either previous laparoscopic cholecystectomy or positive preoperative gallstones. In all, 99 patients met our inclusion criteria and accepted to participate in this trial. After randomization, patients were enrolled in one arm of the study either as a treatment group (group A) or control group (group B), and 10 patients were excluded as illustrated in Flowchart 1.
The remaining 89 patients were allocated as 44 patients in group A, and 45 patients in group B. The studied patients were 55 (65.1%) females and 34 (38.2%) males, and the mean age is 38.1±4.9 years (19.6–59.4 years). The baseline characteristics are illustrated in [Table 1]. There was no statistically significant difference in the age, sex, and preoperative BMI of the patients of both groups. Weight loss parameter changes were expressed in [Table 2], with no statistically significant difference between both the groups.
At the sixth month follow-up, we noticed that 3/44 (6.8%) patients in group A (UDCA treatment) and 10/45 (22.2%) patients in group B (control) developed gallstones, of them only two were symptomatic and had laparoscopic cholecystectomy. Other patients were followed up till the end of the study without any intervention. We found a statistically significant difference between both the groups (P=0.028).
All patients who developed gallstones at 6 months were excluded from the study while assessing the 12 months results to unveil the real percentage of gallstone formation in between 6 and 12 months postoperatively. By US scanning of the remaining patients at the 12th month follow-up, we found 2/38 (5.26%) patients in group A and 5/34 (14.7%) patients had the positive US findings of gallstones. These results (at 12th month) were checked statistically using the nonparametric Mann–Whitney U–test, revealing a statistically significant difference (P=0.031).
Analysis revealed that the overall percentage of gallstones was 23.5% (20/85); it is higher in the first 6 months (14.6%) than in the second 6 months (9.7%) (P=0.043; [Table 3]). No mortality cases were reported in this study.
| Discussion|| |
In the recent era, LSG had emerged as a safe effective bariatric procedure in terms of adequate weight loss and low complication rate. It was observed that approximately 30% of postbariatric surgery patients had gallstones, which are more common during the rapid weight loss phase . Some authors , speculated that the risk of gallstone formation rises markedly if the weight loss exceeds 1.5–1.7 kg/week, or 24% of the initial body weight.
Postbariatric surgery gallstone is considered a controversial topic. It was extensively studied from some aspects as pathophysiology and risk factors. Yet, some other aspects of the natural history and prevention are still vague. Conley et al.  observed that gallstones formed during weight loss have a higher chance to be symptomatic than those formed before LSG. In other words, they behave in a completely different way.
Surprisingly, in a retrospective study conducted in Cleveland Clinic on 796 postbariatric surgery patients, Li et al.  stated that the classic risk factors for gallstone formation in the general population (such as increasing age, female sex, BMI greater than 45 kg/m2, diabetes mellitus, hyperlipidemia) are not the same as that in postbariatric surgery. They found that a weight loss of more than 25% of the original weight is the only postoperative risk factor for cholelithiasis after bariatric surgery.
Furthermore, Paik et al.  found that risk factors for cholelithiasis after gastrectomy for cancer included male sex, increasing age, decreased BMI of more than 4% after gastrectomy, and diabetes mellitus. These risk factors differ markedly from the risk factor after bariatric surgery.
Hence, we can find that different risk factors of cholelithiasis result in different biochemical alterations through vague pathophysiological pathways leading to cholelithiasis.
Gallstone disease may go beyond what is expected and cause significant morbidity. Hence, the prevention of this serious disease is of utmost importance for improving patients’ healthcare and saving the huge cost incurred in the treatment.
Many studies have evaluated the prophylactic role of UDCA following rapid weight loss after AGB, VBG, as well as RYGB ,,,. However, data in the literature about post-LSG gallstones are few. UDCA has been proposed as an effective preventive measure against the gallstone formation during rapid weight loss phase.
Uy et al.  reported in a meta-analysis of five RCTs including 521 patients that UDCA is an effective modality in the prevention of gallstone after bariatric surgery (8.8 vs. 27.7%). In another larger meta-analysis of thirteen RCTs including 1836 patients, Stokes et al.  found that 5% in the UDCA group versus 23% in the control group developed gallstones, and they suggested that UDCA and a high-fat diet may be considered in the primary prevention of gallstones during weight loss. These results were further confirmed by Magouliotis et al.  in another recent meta-analysis of eight studies incorporating 1355 patients.
In a landmark prospective randomized trial conducted by Miller et al.  on 152 patients after VBG and AGB, they reported a less frequent gallstone formation rate in UDCA group in comparison with the placebo group (3 vs. 22% at 1 year, and 8 vs. 30% at 2 years) and also noted a lower rate of cholecystectomy in the UDCA group (4.7 vs. 12%).
Kiewiet et al.  retrospectively assessed the prevalence and risk factors of gallstone formation after AGB in 120 Dutch patients over 9 years without UDCA. They found that the total prevalence of gallstones was 30.1% and stated that UDCA is a cost-effective preventative measure. In addition, Coupaye et al.  found that UDCA decreased the gallstones after RYGB, and they found that it was more efficient if given as 250 mg twice daily than 500-mg single dose.
In this study, analysis of the baseline criteria of the eligible patients revealed a nonsignificant difference between both groups denoting that these variables run evenly in the two study arms, and it had no effect on the final results. In general, US scanning documented that 20/85 patients had gallstones with an overall percentage of 23.5%. This is in range reported by some other studies: Coupaye et al.  found that 15% of their patients developed gallstones, Adams et al.  documented that 17/57 (29.8%) patients developed gallstones, whereas Manatsathit et al.  reported a higher percentage of cholelithiasis (47.9%) in a retrospective cohort study on 96 patients.
The differential statistical analysis of the data of both groups revealed that UDCA has a protective role against gallstones formation after LSG; the rate of gallstones formation in group A is significantly lower than in group B (11.3 vs. 33.3%; P=0.017). Further analysis showed that this protective effect was evident 6 months postoperatively. Such effect is demonstrated through the significant reduction of gallstones formation rate (6.8 vs. 22.2%; P=0.028). Coupaye et al.  found that 13/51 (25.5%) cases developed gallstones in the control group versus only 1/42 (2.4%) case in the UDCA group.
By exclusion of those who developed gallstones and dropout cases, data analysis through Wilcoxon–Mann–Whitney U-test at the 12th month showed again a significant reduction of gallstones (5.2 vs. 14.7%; P=0.031). This could suggest a maintained prophylactic role of UDCA at 12 months after LSG. This is in contrary to the results reported by Adams et al.  who did not find any significant difference in cholelithiasis rate between the two groups at 1 year.
The differential data analysis unveiled also the higher rate of stone formation in the first 6 months that decreased after that till the end of the first year. These results are in accordance with another study  that showed the decrease of cholelithiasis rate from 11 to 9.1% in UDCA group and from 40 to 21.4% in the control group. Similarly, Elgamal and Fawzy  showed a similar pattern with a decreased stone rate from 4.7 to 2.04% in UDCA group and from 11.7 to 5.8% in the control group.
In this context, this dynamic pattern could be attributed to a positive correlation between rapid weight loss and rate of gallstone formation. The underlying cause of this phenomenon is not completely understood. To date, several explanations have been hypothesized based on pathophysiological or biochemical findings like gallbladder hypomotility and bile stasis, increased secretion of mucin and calcium, increased the concentration of prostaglandins and arachidonic acid, and accelerated cholesterol crystal nucleation.In contrast, only one series presented a continuously rising titer of gallstone formation rate, and it was conducted by Miller et al.  on post-VBG and AGB patients; they observed that the rate increased from 22% (at 12th months) to 30% (at 24th months) in the control group and from 3 to 8% in the UDCA group.
Of interest, the incidence of symptomatic gallstones was 3.52% (3/85), which is in accordance with other series (0.7–3.8%) ,,,,. These figures are much lower than that reported after RYGB (4.5–16%) ,,; this could be explained by the preserved enteric–endocrine reflex .
Eleven (8.9%) patients were excluded owing to prior cholecystectomy, which is much lower than reported by another series (32.7%) . Another concern is related to the safety profile of the drug, as only two patients in group A developed adverse effects related to the administration of UDCA such as headache, diarrhea, dizziness, and allergic skin rash, and they discontinued the drug at the seventh and ninth month and were excluded from the data analysis at the 12th month. This small percentage (4.8%) of adverse effects further confirms that UDCA is a safe well-tolerated medication.
In addition, 12 (12.1%) dropout cases were excluded from this series. Miller et al.  had a similarly high rate of dropout cases (18%). They attributed this high figure to the large capsules size that may be difficult to be swallowed after restrictive procedures.
We herein report that this study agrees with the scarce published data about the safety and efficacy of UDCA as a pharmacoprophylactic agent against post-LSG gallstones. The limitations of this current study included the small number of patients and short-term follow-up. The lack of a standardized protocol concerning the prevention of post-LSG gallstones necessitates the design of larger-scale studies with a cost-effective background which could help to establish a consensus for the universal administration of UDCA after LSG.
| Conclusion|| |
Gallstone formation is a common complication after LSG. The incidence of gallstones is higher during the first 6 months postoperatively, which can be correlated with the higher %EWL. It seems that pharmacoprophylaxis by UDCA remains to be a safe effective line of prevention against post-LSG gallstones. Thus, it should be integrated into the post-LSG drug prescription.
The authors made an equal contribution to this study regarding conception, design, literature review, data acquisition, collection and analyses, and writing, editing, and approving the final manuscript.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Mason EE, Renquist KE, Angus G, Baker DJ, Baker JW, Betcher RA et al.
Gallbladder management in obesity surgery. Obes Surg 2002; 12:222–229.
Magouliotis DE, Tasiopoulou VS, Svokos AA, Svokos KA, Chatedaki C, Sioka E et al.
Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: an updated systematic review and meta-analysis. Obes Surg 2017; 27:3021–3030.
Dudric V, Constantea N, Crișan D, Axente D, Silaghi H, Miclăuș D et al.
Laparoscopic sleeve gastrectomy: short and mid-term outcome. Hum Vet Med 2016; 8:171–175.
Käkelä P, Männistö V, Ilves I, Vaittinen M, Tauriainen MM, Eskelinen M et al.
Serum plant sterols associate with gallstone disease independent of weight loss and non-alcoholic fatty liver disease. Obes Surg 2017; 27:1284–1291.
Wudel LJ Jr, Wright JK, Debelak JP, Allos TM, Shyr Y, Chapman WC. Prevention of gallstone formation in morbidly obese patients undergoing rapid weight loss: results of a randomized controlled pilot study. J Surg Res 2002; 102: 50–56.
Dai SL, Zhou J, Yang KX, Yang SY. The expression of hepatic carboxypeptidase E is decreased in patients with cholesterol gallstone. Saudi J Gastroenterol 2015; 21:226–231.
] [Full text]
Coupaye M, Calabrese D, Sami O, Msika S, Ledoux S. Evaluation of incidence of cholelithiasis after bariatric surgery in subjects treated or not treated with ursodeoxycholic acid. Surg Obes Relat Dis 2017; 13:681–685.
Adams LB, Chang C, Pope J, Kim Y, Liu P, Yates A. Randomized, prospective comparison of ursodeoxycholic acid for the prevention of gallstones after sleeve gastrectomy. Obes Surg 2016; 26: 990–994.
Manatsathit W, Leelasinjaroen P, Al-Hamid H, Szpunar S, Hawasli A. The incidence of cholelithiasis after sleeve gastrectomy and its association with weight loss: a two-centre retrospective cohort study. Int J Surg 2016; 30:13–18.
Fuller W, Rasmussen JJ, Ghosh J, Ali MR. Is routine cholecystectomy indicated for asymptomatic cholelithiasis in patients undergoing gastric bypass?. Obes Surg 2007; 6:747–751.
Sioka E, Zacharoulis D, Zachari E, Papamargaritis D, Pinaka O, Katsogridaki G. Complicated gallstones after laparoscopic sleeve gastrectomy. J Obes 2014; 8:1–5.
Conley A, Tarboush M, Manatsathit W, Meguid A, Szpunar S, Hawasli A. Do gallstones found before sleeve gastrectomy behave the same as those formed after surgery due to weight loss? Am J Surg 2016; 212:931–934.
Kiewiet RM, Durian MF, Leersum MV, Hesp FL, Vliet AC. Gallstone formation after weight loss following gastric banding in morbidly obese Dutch patients. Obes Surg 2006; 16:592–596.
Portincasa P, Wang DQ. Effect of inhibition of intestinal cholesterol absorption on the prevention of cholesterol gallstone formation. Med Chem 2017; 13:421–429.
Iguchi Y, Nishimaki-Mogami T, Yamaguchi M, Teraoka F, Kaneko T, Une M. Effects of chemical modification of ursodeoxycholic acid on TGR5 activation. Biol Pharm Bull 2011; 34:1–7.
Pineda O, Maydón HG, Amado M, Sepúlveda EM, Guilbert L, Espinosa O et al.
A prospective study of the conservative management of asymptomatic preoperative and postoperative gallbladder disease in bariatric surgery. Obes Surg 2017; 27:148–153.
Jüngst C, Sreejayan N, Zündt B, Müller I, Spelsberg FW, Hüttl TP et al.
Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones. Eur J Clin Invest 2008; 38:634–639.
Di Ciaula A, Wang D, Wang H, Bonfrate L, Portincasa P. Targets for current pharmacological therapy in cholesterol gallstone disease. Gastroenterol Clin North Am 2010; 39:245–266.
Quesada BM, Kohan G, Roff HE, Canullán CM, Porras LT. Management of gallstones and gallbladder disease in patients undergoing gastric bypass. World J Gastroenterol 2010; 16:2075–2079.
Miller K, Hell E, Lang B, Lengauer E. Gallstone formation prophylaxis after gastric restrictive procedures for weight loss: a randomized double-blind placebo-controlled trial. Ann Surg 2003; 238:697–702.
Papavramidis S, Deligianidis N, Papavramidis T, Sapalidis K, Katsamakas M, Gamvros O. Laparoscopic cholecystectomy after bariatric surgery. Surg Endosc 2003; 17:1061–1064.
Coupaye M, Castel B, Sami O, Tuyeras G, Msika S, Ledoux S. Comparison of the incidence of cholelithiasis after sleeve gastrectomy and Roux-en-Y gastric bypass in obese patients: a prospective study. Surg Obes Relat Dis 2015; 11:779–784.
Li VK, Pulido N, Fajnwaks P, Szomstein S, Rosenthal R. Predictors of gallstone formation after bariatric surgery: a multivariate analysis of risk factors comparing gastric bypass, gastric banding, and sleeve gastrectomy. Surg Endosc 2009; 23:1640–1644.
Paik KH, Lee JC, Kim HW, Kang J, Lee YS, Hwang JH et al.
Risk factors for gallstone formation in resected gastric cancer patients. Medicine 2016; 95:1–6.
Uy MC, Talingdan-Te MC, Espinosa WZ, Daez ML, Ong JP. Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: a meta-analysis. Obes Surg 2008; 18:1532–1538.
Stokes CS, Gluud LL, Casper M, Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2014; 12:1090–1100.
Elgamal A, Fawzy AT. Some risk factors of gallstone formation after laparoscopic sleeve gastrectomy and the role of ezetimibe versus ursodeoxycholic acid in its prevention. Egypt J Intern Med 2014; 26:75–79. [Full text]
Li VK, Pulido N, Martinez-Suartez P, Fajnwaks P, Jin HY, Szomstein S et al.
Symptomatic gallstones after sleeve gastrectomy. Surg Endosc 2009; 23:2488–2492.
Bora G, Sonbahar BÇ, Genç V. Bariatric surgery and gallstone problems. JSM Gastroenterol Hepatol 2017; 5:1078–1082.
[Table 1], [Table 2], [Table 3]